CMC gets the letter.
The warning signs often started upstream.
The batch record that drifted. The OOS that wasn't fully resolved. The validation evidence that no longer matched the operating state.
A CRL is late evidence. The underlying quality signal can exist months earlier — across records no single system evaluates together. That's why we built Clinplex.
Built by the people who lived the fracture.
Regulated operations on one side, production engineering on the other.
Eighteen years in FDA-regulated operations at J&J, AstraZeneca, and Leidos/NCI Frederick across biologics and device manufacturing, CMC, and regulatory affairs. Ran CAPA cycles, 483 responses, and audit remediation before building Clinplex to close the gap between documented compliance and actual compliance posture.
Leads engineering, security, and platform operations. Previously Chief Technology Officer at Critical Mention, where he modernized a network of 170+ globally distributed data centers and scaled the platform to more than 3,000 clients, then Chief Information Officer and Chief Security Officer at Onclusive following the acquisition. Named to PRWeek's Dashboard 25 in 2021 and 2022.
It was all in the records. Nothing read across them.
CRL cites CMC. Root cause isn't there. It's in the batch record that drifted. The OOS nobody closed out. The validation that passed on paper.
Your systems of record are getting smarter. The problem is still the boundary between them.
Veeva, MasterControl, ValGenesis and other regulated platforms increasingly bring AI into the workflows they manage. Clinplex is designed for a different operating boundary: independently evaluating regulatory adequacy across evidence that may span Quality, LIMS, validation, manufacturing, CMC and submissions—regardless of where those records live.
The systems keep their workflows. Clinplex reads across the boundary between them.
A late manufacturing or CMC deficiency can cost another review cycle and months of delay.
Late-stage applications delayed by manufacturing and CMC — not failed clinical efficacy.
Public CRLs show how an otherwise viable application can enter another review cycle because of manufacturing, facility or CMC deficiencies.
Facility-related and data-integrity concerns at a drug-substance manufacturing site prevented FDA from reliably interpreting relevant manufacturing datasets. Efficacy and safety had already been established.
Container-closure incompatibility — glass particles found in clinical batches. Exactly the kind of upstream quality signal Clinplex is built to connect before submission.
of 202 FDA Complete Response Letters released for applications submitted 2020–2024 and subsequently approved involved quality or manufacturing deficiencies.
Figures reflect Clinplex and third-party analyses of public FDA Complete Response Letter data; methodology available on request. CRL examples are drawn from public FDA communications and company disclosures.
Built with the people who know what inspection-ready means.
Strategic advisors on AI/ML and biopharma operations, and domain advisors across validation, CMC, nonclinical review and global regulatory strategy.
Architected the Clinplex engine and its 150+ framework knowledge base. 17+ years building production AI/ML and cloud-scale systems at Microsoft, Salesforce, Quantcast, Take-Two, and Zynga.
MET, Carnegie Mellon.
Immunologist at the NIH, leading research on cytokine therapeutics. Decade+ across preclinical and clinical immunology, biomarker development, and vaccine responses.
Inventor on multiple patents. Associate Editor, Frontiers in Immunology.
Associate Validation Manager at MacroGenics. 20+ years in validation, QC, and regulatory compliance — risk-based validation, equipment qualification, CSV, and 21 CFR Part 11.
Previously Senior QC Analyst at AstraZeneca / MedImmune. BS Biology, Towson. Advises on validation lifecycle and regulatory audits.
CMC Regulatory Affairs Associate Director at AstraZeneca. 15+ years filing global submissions across mAbs, CAR-T, oncology, and vaccines — to FDA, EMA, and global authorities.
Advises on regulatory strategy, CMC documentation, and submission readiness.
Affiliations are listed for background only. Advisors participate in an individual capacity; Clinplex is not endorsed by any listed organization, the FDA, NIH, or any current or former employer.
See the fracture
in your own records.
Send one closed deviation, its CAPA and the governing SOP. Clinplex evaluates whether the three records support the same regulatory conclusion.